
|Videos|October 30, 2013
Other Targets in Ovarian Cancer
Author(s)Michael Birrer, MD, PhD
Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.
Advertisement
Clinical Pearls
Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.
- There is an ongoing debate concerning the ideal use and efficacy of antiangiogenic agents outside of bevacizumab
- The folate receptor is a validated target in ovarian cancer
- Ovarian cancer has not been as well characterized and developed in the immunotherapy space compared to melanoma or renal cell carcinoma
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















